




# WHO guideline for clinical management of exposure to lead







# WHO guideline for clinical management of exposure to lead

WHO guideline for the clinical management of exposure to lead  
ISBN 978-92-4-003704-5 (electronic version)  
ISBN 978-92-4-003705-2 (print version)

© World Health Organization 2021

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization (<http://www.wipo.int/amc/en/mediation/rules/>).

**Suggested citation.** WHO guideline for the clinical management of exposure to lead. Geneva: World Health Organization; 2021. Licence: CC BY-NC-SA 3.0 IGO.

**Cataloguing-in-Publication (CIP) data.** CIP data are available at <http://apps.who.int/iris>.

**Sales, rights and licensing.** To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <https://www.who.int/about/policies/publishing/copyright>.

**Third-party materials.** If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

**General disclaimers.** The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

Cover illustration and design by Optima Graphic Design Consultants Ltd. United Kingdom.

# Contents

**Acknowledgements**

**Abbreviations and acronyms**

---

**Executive summary**

---

## The Guideline

**01 / Purpose and scope**

**02 / Methods for guideline development**

- 2.1 Contributors to the guideline
- 2.2 Identification of priority questions and critical outcomes
- 2.3 Identification and retrieval of evidence
- 2.4 Quality assessment and grading of evidence
- 2.6 Development of recommendations
- 2.7 Good practice statements
- 2.8 Consultation with stakeholders
- 2.9 Document preparation and peer review

**03 / Results of the review**

- 3.1 Guiding principles

**04 / Background**

- 4.1 Principal sources of exposure to lead
- 4.2 Routes of exposure to lead
- 4.3 Toxicokinetics
- 4.4 Toxicity of lead
- 4.5 Toxic effects in relation to blood lead concentrations

**05 / Diagnosis of lead poisoning**

**06 / Recommendation on the blood lead concentration that should initiate clinical interventions**

- 6.1 Introduction
- 6.2 Recommendations for all age groups
- 6.3 Values, equity, feasibility and acceptability of a 5 µg/dL threshold value
- 6.4 Considerations for implementation

**07 / Recommendations for specific treatment interventions**

- 7.1 Gastrointestinal decontamination after ingestion of a lead foreign body or other lead-containing material
- 7.2 Nutritional interventions in children and in pregnant and lactating women exposed to lead
- 7.3 Chelation therapy in individuals exposed to lead

**08 / Integration and implementation of the recommendations in the management of lead poisoning**

- 8.1 Taking a history to identify the source(s) of exposure
- 8.2 Evaluation of the severity of exposure
- 8.3 Reduction and termination of exposure, including improving nutrition
- 8.4 Chelation therapy
- 8.5 Supportive measures
- 8.6 Follow-up

## 09 / **Research gaps**

- 9.1 Gastrointestinal decontamination
- 9.2 Nutritional interventions
- 9.3 Chelation therapy

## 10 / **Considerations for implementation of the guideline**

### **References**

**Annex 1** Members of the WHO Steering Group

**Annex 2** Guideline Development Group

**Annex 3** Research questions and critical and important outcomes

**Annex 4** External reviewers

**Annex 5** Flowcharts summarizing aspects of patient management

**Web Annex** Evidence to decision tables (in preparation)

# Acknowledgements

The development and production of this guideline were coordinated by the World Health Organization (WHO) Department of Environment, Climate Change and Health. The document was prepared by Joanna Tempowski.

Technical guidance is acknowledged from the members of the WHO steering group (in alphabetical order): Ana Boischio (Department of Sustainable Development and Healthy Environment, WHO Regional Office for the Americas); Marie-Noël Bruné Drisse (Department of Environment, Climate Change and Health, WHO headquarters); Mohamed Elmi (Regional Centre for Environmental Health Action, WHO Regional Office for the Eastern Mediterranean); Lesley Onyon (Department of Sustainable Development and Healthy Environment, WHO Regional Office for South-East Asia until 2020, now at the Department of Environment, Climate Change and Health, WHO headquarters); Rokho Kim (Department of Health and the Environment, WHO Regional Office for the Western Pacific, now at the Department of Quality Assurance of Norms and Standards, WHO headquarters); Dorit Nitzan (Ukraine Country Office, now at the Health Emergencies Programme, WHO Regional Office for Europe); Gerry McWeeney, Ukraine Country Office, now at the WHO Office for Representation at the European Union); Annette Prüss-Ustün (Department of Environment, Climate Change and Health, WHO headquarters); Agnes Soares da Silva (Department of Sustainable Development and Healthy Environment, WHO Regional Office for the Americas); and Angelika Tritscher (Department of Food Safety and Zoonoses, WHO headquarters, until 2018).

The technical input of Lisa Rogers and Maria De Las Nieves Garcia Casal of the Department of Nutrition and Food Safety, WHO headquarters, is also acknowledged. The contribution of Lesley Onyon, Department of Environment, Climate Change and Health, WHO headquarters, for guiding this document to its conclusion is noted in particular.

WHO is grateful to Nicola Bates and Heather Wiseman, ESMS Global, London, United Kingdom of Great Britain and Northern Ireland, for their support in conducting the systematic reviews used to inform this guideline. WHO also acknowledges Gerald Gartlehner, Barbara Nussbaumer-Streit and Viktoria Titscher, Danube University Krems, Austria, for providing methodological advice and support for the systematic evidence reviews.

WHO acknowledges the technical input of the guideline development group: Mohammad Abdollahi (Department of Toxicology and Pharmacology, Tehran University of Medical Sciences, Islamic Republic of Iran), Maha Khalid Al Mazrou'a (Regional Poison Control Centre-Dammam, Saudi Arabia), Yona Amitai (Department of Management, Bar Ilan University, Israel), Mary Jean Brown (Harvard Chan School of Public Health, Boston (MA), United States of America (USA)), Chulathida Chomchai (Mahidol University, Nakhon Pathom, Thailand), Paul Dargan (Guy's and St Thomas' National Health Service Foundation Trust, London, United Kingdom), Aruna Dewan (Center for Education, Awareness and Research on Chemicals and Health, Ahmedabad, India), Amalia Laborde (Centre for Toxicological Information and Advice, Faculty of Medicine, Clinical Hospital, Montevideo, Uruguay), Philip J Landrigan (Schiller Institute for Integrated Science and Society, Boston College, Boston (MA), USA), Byung-Kook Lee (Institute of Environmental and Occupational Medicine, Soonchunhyang University, Seoul, Republic of Korea), Angela Mathee (Environment and Health Research Unit, South African Medical Research Council, Johannesburg, South Africa), Nguyen Trung Nguyen (Poisons Centre, Bach Mai Hospital, Hanoi, Viet Nam), Orish E Orisakwe (Toxicology Unit, Faculty of Pharmacy, University of Port Harcourt, Nigeria), Natalie Thurtle (St George's Hospital, Sydney, Australia) and Thuppil Venkatesh (National Referral Centre for Lead Poisoning in India, Bangalore, India). Particular thanks go to David Bellinger (Harvard Medical School Children's Hospital, Boston (MA), USA) for ably chairing the meetings of the guideline development group.

WHO acknowledges the financial support of the Federal Ministry for the Environment, Nature Conservation and Nuclear Safety, Germany; the Department of Health and Social Care, United Kingdom; and the Swedish International Development Cooperation Agency, Sweden, for development and production of this guideline.

# Abbreviations and acronyms

CI	confidence interval
FAO	Food and Agriculture Organization of the United Nations
GRADE	grading of recommendations, assessment, development and evaluation
IQ	intelligence quotient
PbB	blood lead concentration
RCT	randomized controlled trial
TLC	treatment of lead-exposed children
WBI	whole-bowel irrigation

预览已结束，完整报告链接和二维码如下：

[https://www.yunbaogao.cn/report/index/report?reportId=5\\_23537](https://www.yunbaogao.cn/report/index/report?reportId=5_23537)

